查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736691

全球爱滋病毒自检检测套组市场规模（按检测类型、样本类型、应用、区域覆盖范围和预测）

Global HIV Self-Test Kits Market Size By Test Type (Rapid Test Kits, Laboratory-Based Test Kits), By Sample Type (Blood, Saliva), By Application (Home Testing, Laboratory Testing), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

HIV自检检测套组市场规模及预测

2024 年 HIV 自检检测套组市场规模价值 28.7 亿美元，预计到 2032 年将达到 199.7 亿美元，在 2026-2032 年预测期内的复合年增长率为 30.29%。

HIV自检检测套组检测套组是HIV预防和照护领域的重要进步，有助于早期发现和预防HIV，是对抗HIV疫情的宝贵资产。

这些方便、灵敏的工具使个人能够独立评估自己的爱滋病毒状况，从而促进早期发现并促进及时获得医疗服务。

HIV 自我检测套组消除了检测的地理障碍，使居住在偏远和服务不足地区的人们更容易接受检测。

自我测试使个人能够保护自己的隐私并避免与传统测试环境相关的潜在耻辱。

透过自我检测及早发现爱滋病毒感染可以及时进行医疗干预，从而改善健康状况并降低传播风险。

儘管爱滋病毒自检检测套组通常具有较高的准确率，但仍必须密切注意所提供的说明，如果有任何疑问，请寻求医疗建议。

HIV 自我检测套组可能无法检测出最近的感染，因此人们应该在必要时到医疗机构重新接受检测。

全球爱滋病毒自检检测套组市场动态

影响全球爱滋病毒自检检测套组市场的关键市场动态是：

关键市场驱动因素

全球爱滋病毒感染率上升：全球爱滋病毒感染率上升推动了对自检检测套组的需求。联合国爱滋病规划署报告称，2023年全球爱滋病毒感染者人数将达3,840万，比2022年增加2%。 2024年1月15日，OraSure Technologies宣布在东南亚推出其下一代OraQuick爱滋病毒自检检测套组，旨在改善高流行地区的检测可及性。

提高意识，减少污名化：提高意识和减少污名化的努力有助于提高自我检测。世界卫生组织报告称，2023年全球爱滋病毒自我检测率将比2022年增加25%。 2024年3月3日，盖兹基金会承诺捐赠5,000万美元，支持撒哈拉以南非洲地区进行爱滋病毒自我检测宣传活动，并与当地卫生组织合作，推动常规检测的标准化。

HIV 自我检测技术的创新：HIV 自我检测套组的创新正在提高准确性和易用性。 FDA 于 2023 年核准了三种新的 HIV 自我检测技术，增加了检测选项。 2024 年 2 月 20 日，雅培实验室推出了一款可连接智慧型手机的 HIV 自我检测套组，用户可以透过智慧型手机接收数位结果并与医疗保健提供者联繫进行后续护理。

政府推动爱滋病毒自我检测的措施：政府支持的增加正在扩大爱滋病毒自我检测的可及性。美国卫生与公众服务部在2023年为爱滋病毒自我检测计画拨款1.2亿美元，比2022年增加15%。 2024年4月5日，英国政府宣布在全国开展免费爱滋病毒自我检测分发计划，每年覆盖100万人。

主要问题

缺乏意识和污名化阻碍了检测率的提高。许多面临爱滋病毒感染风险的人不愿接受检测，因为他们没有意识到检测的重要性，或面临与爱滋病毒相关的污名化。要消除这些障碍，需要加强公众意识提升宣传活动，并努力减少污名。

缺乏检测机会阻碍早期诊断：检测机会有限，尤其是在医疗资源匮乏和农村地区，可能会阻碍爱滋病毒感染的早期诊断。扩大检测机会，包括透过社区项目，对于应对这项挑战至关重要。

成本障碍阻碍检测：HIV 自检检测套组的成本可能对某些人构成障碍，尤其是在低收入人群中，这可能会限制检测机会并阻碍早期诊断。提供负担得起或津贴的检测方案有助于应对这项挑战。

监管挑战阻碍市场扩张：了解HIV自检检测套组的监管状况可能很复杂，尤其对于在多个司法管辖区运营的製造商和经销商。遵守监管要求会增加成本，并阻碍市场扩张。

主要趋势

远端医疗促进远距检测和咨询：远端医疗的发展正在促进远距爱滋病毒检测和咨询。美国疾病管制与预防中心 (CDC) 报告称，到 2023 年，爱滋病毒自我检测后的远端医疗咨询将增加 40%。 2024 年 3 月 10 日，Hologic 与 Teladoc Health 合作推出了一项整合爱滋病毒自我检测和虚拟咨询的服务，为使用者提供全面的照护。

拓展分销管道：多样化的分销管道正在改善爱滋病毒自检检测套组的可及性。世界卫生组织报告称，到2023年，中低收入国家提供爱滋病毒自检检测套组的药局数量将增加30%。 2024年1月30日，亚马逊宣布将在其医疗保健产品线中纳入经FDA核准的爱滋病毒自检检测套组，从而显着扩大线上查询及性。

精准涵盖重点族群：自检检测套组的广泛普及得益于对重点族群的精准推广。 2024年2月5日，Biosure与巴西的一个LGBTQ+组织合作，免费分发了10万份HIV自我检测套组，重点致力于提高高风险族群的检测率。

监管支持和简化核准：支持性法规正在推动市场成长。欧洲药品管理局于2023年核准了五种新的HIV自检检测套组，并简化了核准流程。 2024年3月25日，世界卫生组织核准了Atomo Diagnostics公司的低成本HIV自我检测检测套组。

目录

第一章 HIV 自检检测套组全球市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章 HIV 自检检测套组的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球HIV自我检测套组市场（依检测类型）

  • 概述
  • 快速检测套组
  • 实验室检测套组

6. 全球HIV自我检测套组市场（依样本类型）

  • 概述
  • 血
  • 尿
  • 唾液

7. 全球HIV自我检测检测套组市场（依应用）

  • 概述
  • 在家测试
  • 就地检验
  • 实验室测试

8. 全球HIV自检检测套组市场（依最终用户）

  • 概述
  • 医院
  • 诊断实验室
  • 专科诊所
  • 研究所
  • 其他的

9. 全球HIV自检检测套组市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

第十章全球HIV自检检测套组市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略
  • 公司地理分布
  • 公司产业布局
  • ACE矩阵

第十一章 公司简介

  • OraSure Technologies Inc.
  • Atomo Diagnostics
  • Chembio Diagnostic Systems Inc.
  • Biosynex Group
  • BioSURE United Kingdom Ltd.
  • ECO Diagnostica
  • bioLytical Laboratories
  • Sedia Biosciences Corporation
  • Orangelife Comercio e Industria LTDA
  • WAMA Diagnostica

第十二章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十三章 附录

  • 相关调查
简介目录
Product Code: 40027

HIV Self-Test Kits Market Size And Forecast

HIV Self-Test Kits Market size was valued at USD 2.87 Billion in 2024 and is projected to reach USD 19.97 Billion by 2032, growing at a CAGR of 30.29% from 2026 to 2032.

HIV self-test kits represent a significant advancement in HIV prevention and care. HIV self-test kits serve as a valuable asset in combating the HIV epidemic by facilitating early detection and promoting prevention efforts.

These convenient and confidential tools empower individuals to assess their HIV status independently, facilitating early detection and facilitating timely access to medical care.

HIV self-test kits offer greater accessibility to individuals residing in remote or underserved regions, eliminating geographical barriers to testing.

Self-testing empowers individuals to maintain privacy and avoid the potential stigma associated with traditional testing settings.

Early detection of HIV infection through self-testing enables prompt medical intervention, leading to improved health outcomes and reduced transmission risk.

HIV self-test kits generally exhibit high accuracy rates, yet it remains essential to follow the provided instructions meticulously and seek medical consultation for any uncertainties.

HIV self-test kits may not detect recent infections, necessitating follow-up testing with a healthcare provider if necessary.

Global HIV Self-Test Kits Market Dynamics

The key market dynamics that are shaping the global HIV self-test kits market include:

Key Market Drivers

Increasing Prevalence of HIV Worldwide: The rising global HIV prevalence is driving demand for self-test kits. UNAIDS reported 38.4 million people living with HIV worldwide in 2023, a 2% increase from 2022. On January 15, 2024, OraSure Technologies announced the launch of its next-generation OraQuick HIV Self-Test in Southeast Asia, aiming to improve access to testing in high-prevalence regions.

Growing Awareness and Reducing Stigma: Efforts to raise awareness and reduce stigma are boosting self-testing adoption. The WHO reported a 25% increase in HIV self-testing volumes globally in 2023 compared to 2022. On March 3, 2024, the Gates Foundation pledged $50 million to support HIV self-testing awareness campaigns in sub-Saharan Africa, partnering with local health organizations to normalize regular testing.

Innovations in HIV Self-Test Technology: Innovations in HIV self-test kits are improving accuracy and user-friendliness. The FDA approved three new HIV self-test technologies in 2023, enhancing testing options. On February 20, 2024, Abbott Laboratories unveiled a smartphone-connected HIV self-test kit, allowing users to receive digital results and connect with healthcare providers for follow-up care.

Government Initiatives Promoting HIV Self-Testing: Increased government support is expanding access to HIV self-testing. The U.S. Department of Health and Human Services allocated $120 million for HIV self-testing programs in 2023, a 15% increase from 2022. On April 5, 2024, the UK government announced a nationwide free HIV self-test distribution program, aiming to reach 1 million people annually.

Key Challenges:

Limited Awareness and Stigma Hindering Testing Rates: Many individuals at risk for HIV infection may not be aware of the importance of testing or may face stigma associated with HIV, deterring them from seeking testing. Addressing these barriers requires increased public awareness campaigns and efforts to reduce stigma.

Lack of Access to Testing Facilities Hampering Early Diagnosis: Limited availability of testing facilities, particularly in underserved or rural areas, can hinder early diagnosis of HIV infection. Expanding access to testing facilities, including through community-based programs, is crucial for addressing this challenge.

Cost Barriers Obstructing Access to Testing: The cost of HIV self-test kits may be a barrier for some individuals, particularly in low-income communities. This can limit access to testing and prevent early diagnosis. Providing affordable or subsidized testing options can help address this challenge.

Regulatory Hurdles Challenging Market Expansion: Navigating the regulatory landscape for HIV self-test kits can be complex, especially for manufacturers and distributors operating in multiple jurisdictions. Compliance with regulatory requirements can increase costs and hinder market expansion.

Key Trends

Telemedicine Facilitating Remote Testing and Counseling: The growth of telemedicine is facilitating remote HIV testing and counseling. The CDC reported a 40% increase in telehealth consultations following HIV self-tests in 2023. On March 10, 2024, Hologic partnered with Teladoc Health to launch an integrated HIV self-testing and virtual counseling service, providing comprehensive care to users.

Expanding Distribution Channels: Diverse distribution channels are improving access to HIV self-test kits. The WHO reported a 30% increase in pharmacies offering HIV self-test kits in low- and middle-income countries in 2023. On January 30, 2024, Amazon announced the inclusion of FDA-approved HIV self-test kits in its healthcare product line, significantly expanding online access to testing.

Targeted Efforts to Reach Key Populations: Targeted efforts to reach key populations are driving self-test kit adoption. On February 5, 2024, BioSure partnered with LGBTQ+ organizations in Brazil to distribute 100,000 free HIV self-test kits, focusing on improving testing rates in high-risk communities.

Regulatory Support and Streamlined Approvals: Supportive regulations are accelerating market growth. The European Medicines Agency approved five new HIV self-test kits in 2023, streamlining the approval process. On March 25, 2024, the WHO prequalified a new low-cost HIV self-test from Atomo Diagnostics, paving the way for increased access in resource-limited settings and driving global market expansion.

Global HIV Self-Test Kits Market Regional Analysis

Here is a more detailed regional analysis of the global HIV self-test kits market:

North America

North America is dominating the HIV self-test kits market, driven by advanced healthcare infrastructure and strong awareness campaigns.

According to the Centers for Disease Control and Prevention (CDC), HIV self-testing in the United States increased by 35% in 2023 compared to the previous year, with over 2.5 million self-tests distributed.

The region's market leadership is also supported by favorable government policies and innovative public health initiatives.

Health Canada reported that 78% of new HIV diagnoses in 2023 were initially detected through self-testing, highlighting its effectiveness in early detection.

On March 15, 2024, Abbott Laboratories launched a nationwide campaign in collaboration with the U.S. Department of Health and Human Services, aiming to distribute 1 million free HIV self-test kits to underserved communities over the next year.

This initiative, coupled with the increasing integration of self-testing into routine healthcare practices, further solidifies North America's position at the forefront of the global HIV self-test kits market.

Asia-Pacific

The Asia-Pacific region is projected to experience a rapid CAGR growth during the forecast period, driven by the increasing awareness, government initiatives, and improving healthcare access.

According to the World Health Organization's Western Pacific Regional Office, HIV self-testing uptake in the region increased by 62% in 2023 compared to the previous year.

This growth was further accelerated on January 20, 2024, when the Chinese government announced a nationwide program to distribute 5 million free HIV self-test kits annually, partnering with local manufacturer Wondfo Biotech to ensure widespread availability.

The region's market expansion is also fueled by technological advancements and strategic collaborations. India's National AIDS Control Organisation reported a 45% increase in HIV self-testing among high-risk populations in 2023, largely attributed to mobile health initiatives.

On March 5, 2024, Mylan Pharmaceuticals (now part of Viatris) launched a smartphone-connected HIV self-test kit in Southeast Asia, starting with Thailand and Vietnam.

This innovation, coupled with a partnership announced on April 1, 2024, between the Bill & Melinda Gates Foundation and several APAC countries to subsidize self-test kits, underscores the region's potential for continued rapid growth in the HIV self-test kits market.

Global HIV Self-Test Kits Market: Segmentation Analysis

The Global HIV Self-Test Kits Market is segmented based on Test Type, Sample Type, Application, and Geography.

HIV Self-Test Kits Market, By Test Type

  • Rapid Test Kits
  • Laboratory-Based Test Kits

Based on Test Type, the Global HIV Self-Test Kits Market is bifurcated into Rapid Test Kits, Laboratory-Based Test Kits. The rapid test kits segment maintains a dominant position within the HIV self-test kit market, favored for their convenience, affordability, and ease of use. These tests offer rapid results, enabling prompt decision-making and access to medical care. However, the laboratory-based test kits segment is experiencing rapid growth, driven by their superior sensitivity and specificity, making them indispensable for confirming HIV diagnoses and monitoring viral load.

HIV Self-Test Kits Market, By Sample Type

  • Blood
  • Saliva
  • Urine

Based on Sample Type, the Global HIV Self-Test Kits Market is bifurcated into Blood, Saliva, Urine. The blood segment is dominating the HIV self-test kit market, driven by its high accuracy and reliability in detecting HIV antibodies. However, the saliva segment is experiencing rapid growth, as saliva-based tests offer a less invasive and more convenient option for testing.

HIV Self-Test Kits Market, By Application

  • Home Testing
  • Point-of-Care Testing
  • Laboratory Testing

Based on Application, the Global HIV Self-Test Kits Market is bifurcated into Home Testing, Point-of-Care Testing, Laboratory Testing. The home testing segment is currently dominating the HIV self-test kit market, driven by the convenience and privacy that self-testing offers. However, the point-of-care testing segment is experiencing rapid growth, as healthcare providers are increasingly adopting rapid HIV tests for quick and efficient diagnosis in clinical settings.

HIV Self-Test Kits Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the Global HIV Self-Test Kits Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American region continues to dominate the global HIV self-test kits market, driven by the advanced healthcare infrastructure and strong awareness campaigns. However, the Asia-Pacific region is projected to experience a rapid CAGR growth during the forecast period, driven by increasing awareness, government initiatives, and improving healthcare access.

Key Players

The "Global HIV Self-Test Kits Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are SD Biosensor, CTK Biotech, Genedrive Plc, Hyrex Diagnostics, Trinity Biotech, Mylan Laboratories, BioSure, PerkinElmer, Acon Laboratories, OraSure Technologies, Vestergaard Frandsen, Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, MP Biomedicals.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global HIV Self-Test Kits Market Key Developments

  • In February 2023, Mylab Discovery Solutions, announced the launch of three new rapid kits for the quick and early diagnosis of STIs, including as syphilis, hepatitis C virus, and HIV.
  • In November 2022, in an effort to further diagnostic solutions, Chembio Diagnostics applied for a CLIA waiver from the FDA for their DPP HIV-Syphilis System.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL HIV SELF-TEST KITS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HIV SELF-TEST KITS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter's Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HIV SELF-TEST KITS MARKET, BY TEST TYPE

  • 5.1 Overview
  • 5.2 Rapid Test Kits
  • 5.3 Laboratory-Based Test Kits

6 GLOBAL HIV SELF-TEST KITS MARKET, BY SAMPLE TYPE

  • 6.1 Overview
  • 6.2 Blood
  • 6.3 Urine
  • 6.4 Saliva

7 GLOBAL HIV SELF-TEST KITS MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Home Testing
  • 7.3 Point-of-Care Testing
  • 7.4 Laboratory Testing

8 GLOBAL HIV SELF-TEST KITS MARKET, BY END-USER

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Diagnostic Laboratories
  • 8.4 Specialty Clinics
  • 8.5 Research Institutes
  • 8.6 Others

9 GLOBAL HIV SELF-TEST KITS MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 The U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 The U.K.
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of LATAM
  • 9.6 Middle East and Africa
    • 9.6.1 UAE
    • 9.6.2 Saudi Arabia
    • 9.6.3 South Africa
    • 9.6.4 Rest of the Middle East and Africa

10 GLOBAL HIV SELF-TEST KITS MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Development Strategies
  • 10.4 Company Regional Footprint
  • 10.5 Company Industry Footprint
  • 10.6 ACE Matrix

11 COMPANY PROFILES

  • 11.1 OraSure Technologies Inc.
    • 11.1.1 Company Overview
    • 11.1.2 Company Insights
    • 11.1.3 Business Breakdown
    • 11.1.4 Product Benchmarking
    • 11.1.5 Key Developments
    • 11.1.6 Winning Imperatives
    • 11.1.7 Current Focus & Strategies
    • 11.1.8 Threat from Competition
    • 11.1.9 SWOT Analysis
  • 11.2 Atomo Diagnostics
    • 11.2.1 Company Overview
    • 11.2.2 Company Insights
    • 11.2.3 Business Breakdown
    • 11.2.4 Product Benchmarking
    • 11.2.5 Key Developments
    • 11.2.6 Winning Imperatives
    • 11.2.7 Current Focus & Strategies
    • 11.2.8 Threat from Competition
    • 11.2.9 SWOT Analysis
  • 11.3 Chembio Diagnostic Systems Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Business Breakdown
    • 11.3.4 Product Benchmarking
    • 11.3.5 Key Developments
    • 11.3.6 Winning Imperatives
    • 11.3.7 Current Focus & Strategies
    • 11.3.8 Threat from Competition
    • 11.3.9 SWOT Analysis
  • 11.4 Biosynex Group
    • 11.4.1 Company Overview
    • 11.4.2 Company Insights
    • 11.4.3 Business Breakdown
    • 11.4.4 Product Benchmarking
    • 11.4.5 Key Developments
    • 11.4.6 Winning Imperatives
    • 11.4.7 Current Focus & Strategies
    • 11.4.8 Threat from Competition
    • 11.4.9 SWOT Analysis
  • 11.5 BioSURE United Kingdom Ltd.
    • 11.5.1 Company Overview
    • 11.5.2 Company Insights
    • 11.5.3 Business Breakdown
    • 11.5.4 Product Benchmarking
    • 11.5.5 Key Developments
    • 11.5.6 Winning Imperatives
    • 11.5.7 Current Focus & Strategies
    • 11.5.8 Threat from Competition
    • 11.5.9 SWOT Analysis
  • 11.6 ECO Diagnostica
    • 11.6.1 Overview
    • 11.6.2 Financial Performance
    • 11.6.3 Product Outlook
    • 11.6.4 Key Development
  • 11.7 bioLytical Laboratories
    • 11.7.1 Overview
    • 11.7.2 Financial Performance
    • 11.7.3 Product Outlook
    • 11.7.4 Key Developments
  • 11.8 Sedia Biosciences Corporation
    • 11.8.1 Overview
    • 11.8.2 Financial Performance
    • 11.8.3 Product Outlook
    • 11.8.4 Key Development
  • 11.9 Orangelife Comercio e Industria LTDA
    • 11.9.1 Overview
    • 11.9.2 Financial Performance
    • 11.9.3 Product Outlook
    • 11.9.4 Key Development
  • 11.10 WAMA Diagnostica
    • 11.10.1 Overview
    • 11.10.2 Financial Performance
    • 11.10.3 Product Outlook
    • 11.10.4 Key Development

12 KEY DEVELOPMENTS

  • 12.1 Product Launches/Developments
  • 12.2 Mergers and Acquisitions
  • 12.3 Business Expansions
  • 12.4 Partnerships and Collaborations

13 Appendix

  • 13.1 Related Research